A citation-based method for searching scientific literature

A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
Times Cited: 105







List of co-cited articles
846 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
Jun Shirakawa, Hideki Fujii, Kei Ohnuma, Koichiro Sato, Yuzuru Ito, Mitsuyo Kaji, Eri Sakamoto, Megumi Koganei, Hajime Sasaki, Yoji Nagashima,[...]. Diabetes 2011
180
24

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Daniela Lamers, Susanne Famulla, Nina Wronkowitz, Sonja Hartwig, Stefan Lehr, D Margriet Ouwens, Kristin Eckardt, Jean M Kaufman, Mikael Ryden, Stefan Müller,[...]. Diabetes 2011
372
21

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Zubair Shah, Thomas Kampfrath, Jeffrey A Deiuliis, Jixin Zhong, Colleen Pineda, Zhekang Ying, Xiaohua Xu, Bo Lu, Susan Moffatt-Bruce, Rekha Durairaj,[...]. Circulation 2011
266
19

Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
171
18


Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.
Y-S Lee, M-S Park, J-S Choung, S-S Kim, H-H Oh, C-S Choi, S-Y Ha, Y Kang, Y Kim, H-S Jun. Diabetologia 2012
131
15

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Gian Paolo Fadini, Elisa Boscaro, Mattia Albiero, Lisa Menegazzo, Vera Frison, Saula de Kreutzenberg, Carlo Agostini, Antonio Tiengo, Angelo Avogaro. Diabetes Care 2010
250
14

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Liliana Ferreira, Edite Teixeira-de-Lemos, Filipa Pinto, Belmiro Parada, Cristina Mega, Helena Vala, Rui Pinto, Patrícia Garrido, José Sereno, Rosa Fernandes,[...]. Mediators Inflamm 2010
123
14


A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Noriko Satoh-Asahara, Yousuke Sasaki, Hiromichi Wada, Mayu Tochiya, Azusa Iguchi, Reiko Nakagawachi, Shinji Odori, Shigeo Kono, Koji Hasegawa, Akira Shimatsu. Metabolism 2013
124
13

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
84
14

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,[...]. J Am Coll Cardiol 2012
207
12

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
12

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
11


Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck, Gordon S Howarth, Catherine A Abbott. Trends Pharmacol Sci 2009
179
11

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
James Mu, John Woods, Yun-Ping Zhou, Ranabir Sinha Roy, Zhihua Li, Emanuel Zycband, Yue Feng, Lan Zhu, Cai Li, Andrew D Howard,[...]. Diabetes 2006
351
10

Obesity is associated with macrophage accumulation in adipose tissue.
Stuart P Weisberg, Daniel McCann, Manisha Desai, Michael Rosenbaum, Rudolph L Leibel, Anthony W Ferrante. J Clin Invest 2003
10

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Gian Paolo Fadini, Angelo Avogaro. Vascul Pharmacol 2011
158
10

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
611
10

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
F Vittone, A Liberman, D Vasic, R Ostertag, M Esser, D Walcher, A Ludwig, N Marx, M Burgmaier. Diabetologia 2012
72
13

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.
Stacey L Conarello, Zhihua Li, John Ronan, Ranabir Sinha Roy, Lan Zhu, Guoqiang Jiang, Franklin Liu, John Woods, Emanuel Zycband, David E Moller,[...]. Proc Natl Acad Sci U S A 2003
257
10


DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue.
K Kos, A R Baker, M Jernas, A L Harte, J C Clapham, J P O'Hare, L Carlsson, S Kumar, P G McTernan. Diabetes Obes Metab 2009
58
15

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Nga N Ta, Corinne A Schuyler, Yanchun Li, Maria F Lopes-Virella, Yan Huang. J Cardiovasc Pharmacol 2011
120
9

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
A J Tremblay, B Lamarche, C F Deacon, S J Weisnagel, P Couture. Diabetes Obes Metab 2011
119
9

Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Limei Liu, Jian Liu, Wing Tak Wong, Xiao Yu Tian, Chi Wai Lau, Yi-Xiang Wang, Gang Xu, Yunfei Pu, Zhiming Zhu, Aimin Xu,[...]. Hypertension 2012
134
9


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
9

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
8

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.
Haiyan Xu, Glenn T Barnes, Qing Yang, Guo Tan, Daseng Yang, Chieh J Chou, Jason Sole, Andrew Nichols, Jeffrey S Ross, Louis A Tartaglia,[...]. J Clin Invest 2003
8

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
Goutam C Mistry, Andrea L Maes, Kenneth C Lasseter, Michael J Davies, Keith M Gottesdiener, John A Wagner, Gary A Herman. J Clin Pharmacol 2008
167
8

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
N Matikainen, S Mänttäri, A Schweizer, A Ulvestad, D Mills, B E Dunning, J E Foley, M-R Taskinen. Diabetologia 2006
246
8






Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
Catarina Marques, Cristina Mega, Andreia Gonçalves, Paulo Rodrigues-Santos, Edite Teixeira-Lemos, Frederico Teixeira, Carlos Fontes-Ribeiro, Flávio Reis, Rosa Fernandes. Mediators Inflamm 2014
74
10

Type 2 diabetes as an inflammatory disease.
Marc Y Donath, Steven E Shoelson. Nat Rev Immunol 2011
7

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.
Zubair Shah, Colleen Pineda, Thomas Kampfrath, Andrei Maiseyeu, Zhekang Ying, Ira Racoma, Jeffrey Deiuliis, Xiaohua Xu, Qinghua Sun, Susan Moffatt-Bruce,[...]. Vascul Pharmacol 2011
117
7

Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.
R Preston Mason, Robert F Jacob, Ruslan Kubant, Mary F Walter, Aouatef Bellamine, Adam Jacoby, Yoshiko Mizuno, Tadeusz Malinski. J Atheroscler Thromb 2011
41
17


Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Masayuki Arakawa, Tomoya Mita, Kosuke Azuma, Chie Ebato, Hiromasa Goto, Takashi Nomiyama, Yoshio Fujitani, Takahisa Hirose, Ryuzo Kawamori, Hirotaka Watada. Diabetes 2010
346
7


Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
725
7

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
Takanori Matsui, Yuri Nishino, Masayoshi Takeuchi, Sho-ichi Yamagishi. Pharmacol Res 2011
76
9

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.
Y Takeda, Y Fujita, J Honjo, T Yanagimachi, H Sakagami, Y Takiyama, Y Makino, A Abiko, T J Kieffer, M Haneda. Diabetologia 2012
91
7


Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.
Bruna Pm Pacheco, Renato O Crajoinas, Gisele K Couto, Ana Paula C Davel, Lucília M Lessa, Luciana V Rossoni, Adriana Cc Girardi. J Hypertens 2011
95
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.